candesartan has been researched along with Hyperemia in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Hyperemia: The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. Hyperemia can be due to increase of blood flow into the area (active or arterial), or due to obstruction of outflow of blood from the area (passive or venous).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both candesartan and perindopril can prevent FFA-induced myocardial microcirculatory dysfunction during hyperemia via modulation of leukocyte activation and microvascular endothelial function." | 3.88 | Renin-Angiotensin System Inhibitors Can Prevent Intravenous Lipid Infusion-Induced Myocardial Microvascular Dysfunction and Leukocyte Activation. ( Kikuchi, Y; Kobayashi, M; Momomura, S; Mutoh, A; Ueda, S; Wada, H; Yasu, T, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yasu, T | 1 |
| Mutoh, A | 1 |
| Wada, H | 1 |
| Kobayashi, M | 1 |
| Kikuchi, Y | 1 |
| Momomura, S | 1 |
| Ueda, S | 1 |
1 other study available for candesartan and Hyperemia
| Article | Year |
|---|---|
Renin-Angiotensin System Inhibitors Can Prevent Intravenous Lipid Infusion-Induced Myocardial Microvascular Dysfunction and Leukocyte Activation.
Topics: Adult; Benzimidazoles; Biphenyl Compounds; Coronary Circulation; Cross-Over Studies; Double-Blind Me | 2018 |